ATLAS News · Companies

SELLAS Life Sciences posts Q3 loss of $10.1M, flags Phase 3 AML data

Published November 12, 2026 · 6 sources

SELLAS Life Sciences reported Q3 2026 results, with $134.7 million in cash and topline Phase 3 REGAL trial results in AML expected this month.

What happened

SELLAS Life Sciences Group (NASDAQ: SLS) reported financial results for the third quarter and nine months ended September 30, 2026, according to MarketScreener and Yahoo Finance. Crypto Briefing reports a quarterly loss of $10.1 million.

The company's update says topline primary endpoint results of the Phase 3 REGAL trial of Galinpepimut-S (GPS) in acute myeloid leukemia are expected this month, following the 80th event. SELLAS also said 40 patients are enrolled in its Phase 2 trial of SLS009 in newly diagnosed first-line AML, with preliminary topline data expected in Q4 2026.

The company reported $134.7 million in cash and cash equivalents as of September 30, 2026. Yahoo Finance and Seeking Alpha noted that shares rose after hours as the company described the upcoming Phase 3 results as transformative.

Context

Phase 3 trials are the late stage of clinical testing, and their results often shape a drug developer's regulatory and financial path.

Why it matters

The REGAL readout is a key event for SELLAS, and its outcome could be significant for the company and its shareholders.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

SELLAS Life Sciences GroupSLS

−4.63%

Healthcare · NASDAQ

Live price

$8.24▼ -4.63%

live price · USD

Close on November 12: $8.03−4.63% vs. previous close ($8.42)
Chance of a rise in 1 month: 44%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $6.67 and $9.46; 9 in 10, between $4.89 and $12.90.

See the full ATLAS analysis of SELLAS Life Sciences Group →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 · www.marketscreener.com · November 12, 2026
SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update · Yahoo Finance · November 12, 2026
SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach · Crypto Briefing · November 12, 2026
SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Month · Yahoo Finance · November 13, 2026
Sellas Life Sciences shares jump as key leukemia trial results near (SLS:NASDAQ) · Seeking Alpha · November 13, 2026
Sellas Life Sciences shares jump as key leukemia trial results near · TradingView · November 13, 2026

Latest market news · Markets today on ATLAS · SELLAS Life Sciences Group

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer